Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegaly PR...
Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorder PR Newswire LUND, Sweden, May 24, 2023...
Braeburn receives new Complete Response Letter for Brixadi in the US PR Newswire LUND, Sweden, Dec. 15, 2021 LUND, Sweden, Dec. 15, 2021...
FDA grants Orphan Drug Designation in the US for CAM2029 for the treatment of polycystic liver disease PR Newswire LUND, Sweden, Sept. 16, 2021...
Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the US PR Newswire LUND, Sweden, June 26, 2021 New PDUFA...
Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the US New PDUFA action date for Brixadi set for 15 December...
Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the US PR Newswire LUND, Sweden, June 15, 2021 LUND, Sweden, June 15...
Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injections in opioid...
The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependence PR Newswire LUND, Sweden, May 3, 2021 LUND, Sweden...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads